Skip to main content

Rezipres FDA Approval History

Last updated by Judith Stewart, BPharm on June 15, 2021.

FDA Approved: Yes (First approved June 14, 2021)
Brand name: Rezipres
Generic name: ephedrine hydrochloride
Dosage form: Injection
Company: Eton Pharmaceuticals, Inc.
Treatment for: Hypotension

Rezipres (ephedrine hydrochloride) is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

  • Rezipres is a sulfite-free ephedrine formulation containing ephedrine hydrochloride.
  • Rezipres is administered intravenously as a bolus injection.
  • Common adverse reactions include nausea, vomiting, and tachycardia.

Development timeline for Rezipres

DateArticle
Jun 15, 2021Approval FDA Approves Rezipres (ephedrine hydrochloride injection) for Hypotension During Anesthesia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.